<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925261</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-100</org_study_id>
    <nct_id>NCT01925261</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrthoTrophix, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OrthoTrophix, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This one-year study is designed to investigate the safety and efficacy of TPX-100, a 23-amino&#xD;
      acid chondrogenic peptide, delivered by intra-articular injection, in regeneration of knee&#xD;
      cartilage in subjects with bilateral osteoarthritis of the knee.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cartilage thickness in the patello-femoral compartment as measured on standardized MRI from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in cartilage thickness in the patello-femoral compartment from baseline to 12 months</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>TPX-100 Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 1 will be 20mg dose of TPX-100 in one randomized knee, compared to placebo treated knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPX-100 Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 2 will be 50mg dose of TPX-100 in one randomized knee compared to placebo treated knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPX-100 Cohort 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 3 will be 100mg dose of TPX-100 in one randomized knee compared to placebo treated knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPX-100 Cohort 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 4 will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPX-100 50mg</intervention_name>
    <arm_group_label>TPX-100 Cohort 2</arm_group_label>
    <other_name>50mg of TPX-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPX-100 100mg</intervention_name>
    <arm_group_label>TPX-100 Cohort 3</arm_group_label>
    <other_name>100mg of TPX-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPX-100 200mg</intervention_name>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>TPX-100 Cohort 4</arm_group_label>
    <other_name>200mg of TPX-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPX-100 20mg</intervention_name>
    <arm_group_label>TPX-100 Cohort 1</arm_group_label>
    <other_name>20mg of TPX-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>TPX-100 Cohort 1</arm_group_label>
    <arm_group_label>TPX-100 Cohort 2</arm_group_label>
    <arm_group_label>TPX-100 Cohort 3</arm_group_label>
    <arm_group_label>TPX-100 Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 25 and ≤ 75&#xD;
&#xD;
          2. Patello-femoral osteoarthritis of both knees of mild to moderate severity with intact&#xD;
             meniscus and ligamentous stability (cruciate and collateral ligaments)&#xD;
&#xD;
               -  Clinically, as determined by screening questionnaire and judgment of the&#xD;
                  Principal Investigator (may be supported by imaging studies of knees); confirmed&#xD;
                  by centrally read screening MRI of both knees indicating ICRS Grade 1-3, or ICRS&#xD;
                  Grade 4 with only focal defects, no greater than 1 cm.&#xD;
&#xD;
               -  Meniscus intact (MRI degenerative signal up to and including grade II acceptable)&#xD;
&#xD;
               -  Cruciate and collateral ligament stability as defined by clinical examination&#xD;
&#xD;
          3. Able to read, understand, sign and date the subject informed consent&#xD;
&#xD;
          4. Willingness to use only acetaminophen as the primary analgesic (pain-relieving) study&#xD;
             medication. The maximum dose of acetaminophen must not exceed 4 grams/day (4000 mg per&#xD;
             day).&#xD;
&#xD;
          5. Willingness to use only hydrocodone/acetaminophen for breakthrough pain during the&#xD;
             injection period (through study day 30).&#xD;
&#xD;
          6. Willingness not to use non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin,&#xD;
             ibuprofen, naproxen for the first 30 days of the study.&#xD;
&#xD;
          7. Female subjects of child bearing potential who are sexually active (non-abstinent)&#xD;
             must agree to and comply with using 2 highly effective methods of birth control (oral&#xD;
             contraceptive, implant, injectable or indwelling intrauterine device, condom with&#xD;
             spermicide, or sexual abstinence) while participating in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to MRI, including: metallic fragments, clips or devices in the brain,&#xD;
             eye, or spinal canal; implanted devices that are magnetically programmed; weight &gt; 300&#xD;
             lbs.; moderate or severe claustrophobia; previous intolerance of MRI procedure&#xD;
&#xD;
          2. ICRS grade greater than Grade 3, or Grade 4 focal defects greater than 1 cm, as&#xD;
             confirmed by centrally-read screening MRI&#xD;
&#xD;
          3. MRI evidence of inflammatory or hypertrophic synovitis&#xD;
&#xD;
          4. Prior surgery in the knees, excluding procedures for debridement only (no&#xD;
             microfracture)&#xD;
&#xD;
          5. Joint replacement or any other knee surgery planned in the next 12 months&#xD;
&#xD;
          6. History of rheumatoid arthritis, psoriatic arthritis, or any other autoimmune or&#xD;
             infectious cause for arthritis&#xD;
&#xD;
          7. Knee effusion &gt;2+ on the following clinical scale:&#xD;
&#xD;
               -  Zero = No wave produced on downstroke&#xD;
&#xD;
               -  Trace = Small wave on medial side with downstroke&#xD;
&#xD;
               -  1+ = Larger bulge on medial side with downstroke&#xD;
&#xD;
               -  2+ = Effusion spontaneously returns to medial side after upstroke (no downstroke&#xD;
                  necessary)&#xD;
&#xD;
               -  3+ = So much fluid that it is not possible to move the effusion out of the medial&#xD;
                  aspect of the knee&#xD;
&#xD;
          8. Last viscosupplementation (e.g. Synvisc® or similar hyaluronic acid product) injected&#xD;
             into either knee &lt; 3 months before screening&#xD;
&#xD;
          9. Last intra-articular knee injection of corticosteroids &lt; 2 months before screening&#xD;
&#xD;
         10. Use of any steroids (except inhaled corticosteroids for respiratory problems) during&#xD;
             the previous month before screening&#xD;
&#xD;
         11. Known hypersensitivity to TPX-100&#xD;
&#xD;
         12. Known hypersensitivity to acetaminophen or hydrocodone&#xD;
&#xD;
         13. History of arthroscopy in either knee in the last 3 months before screening&#xD;
&#xD;
         14. History of septic arthritis, gout or pseudo-gout, of either knee in previous year&#xD;
             before screening&#xD;
&#xD;
         15. Clinical signs of acute meniscal tear (locking, new acute mechanical symptoms&#xD;
             consistent with meniscal tear)&#xD;
&#xD;
         16. Patellar chondrocalcinosis on X-Ray&#xD;
&#xD;
         17. Skin problem, rash or hypersensitivity, affecting either knee at the injection site&#xD;
&#xD;
         18. Bleeding problem, platelet or coagulation deficiency contraindicating, in the doctor's&#xD;
             opinion, any intra-articular injection&#xD;
&#xD;
         19. Active systemic infection&#xD;
&#xD;
         20. Current treatment or treatment within the previous 2 years prior to the Screening&#xD;
             Visit for any malignancy except basal cell or squamous cell carcinoma of the skin,&#xD;
             unless with specific written permission is provided by the Sponsor's medical monitor&#xD;
&#xD;
         21. Women of childbearing potential who are pregnant, nursing, or planning to become&#xD;
             pregnant, and those who do not agree to remain on an acceptable method of birth&#xD;
             control throughout the entire study period&#xD;
&#xD;
         22. Participation in other clinical osteoarthritis drug studies within one year prior to&#xD;
             screening&#xD;
&#xD;
         23. Currently taking Paclitaxel (mitotic inhibitor), and or Natalizumab (anti-integrin&#xD;
             monoclonal antibody).&#xD;
&#xD;
         24. History of significant liver disease or consumption of more than 3 alcoholic drinks a&#xD;
             day. (Definition of one alcoholic drink: 12-ounces of beer, 8-ounces of malt liquor,&#xD;
             5-ounces of wine, 1.5-ounces or a &quot;shot&quot; of 80-proof distilled spirits or liquor such&#xD;
             as gin, rum, vodka, or whiskey).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>C3 Clinical Research Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2013</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>knee osteoarthritis</keyword>
  <keyword>bilateral</keyword>
  <keyword>osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 23, 2018</submitted>
    <returned>May 30, 2018</returned>
    <submitted>June 27, 2018</submitted>
    <returned>July 23, 2018</returned>
    <submitted>August 21, 2018</submitted>
    <returned>September 19, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

